The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Efficacy of Celsi Warmer for the Management of Hypothermic Newborns at the Lagos University Teaching Hospital in Lagos, Nigeria

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT06003140
Recruitment Status : Recruiting
First Posted : August 21, 2023
Last Update Posted : August 23, 2023
Sponsor:
Collaborator:
University of Lagos, Nigeria
Information provided by (Responsible Party):
William Marsh Rice University

Brief Summary:
The prevalence of hypothermia across low-resource settings is high, especially in countries with high neonatal mortality rates. If left untreated, hypothermia can additionally result in a significant comorbidity, and has been linked to a reduction in the effectiveness of treatment for other newborn conditions. Effective thermal care for hypothermic newborns is not widely available in low-resource settings due to cost of consumables and spare parts. In this study, the research team wish to evaluate the efficacy of a novel neonatal warming mattress in treating hypothermic newborns. Warming mattress, 'Celsi Warmer', has been developed by Rice 360 Institute for Global Health Technologies, in conjunction with African clinicians, to be a robust, low-cost, and easy-to-use warming mattress which can address the challenges of hypothermia. This is a single-arm, non-randomized, prospective intervention study. Up to 90 eligible infants at the neonatal wards of the Lagos University Teaching Hospital will be recruited to evaluate the efficacy of Celsi Warmer in rewarming hypothermic newborns. Infants temperature will be monitored during thermal intervention and the performance of the device will be evaluated. The temperatures of each infant will be compared before, during, and after the intervention.

Condition or disease Intervention/treatment Phase
Neonatal Hypothermia Device: Celsi Warmer Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 90 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Efficacy of Low-cost Warming Mattress Celsi Warmer for the Management of Hypothermic Newborns at the Lagos University Teaching Hospital in Lagos, Nigeria
Estimated Study Start Date : August 15, 2023
Estimated Primary Completion Date : October 21, 2024
Estimated Study Completion Date : October 21, 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Hypothermia

Arm Intervention/treatment
Experimental: Hypothermic Neonates (90)
A trained study clinician will attach the Celsi Warmer temperature sensor to the abdomen and secure it with the abdominal belt according to the device's instruction manual (such that the temperature sensor is positioned using a vertical line from the mid-clavicular line and just below the ribs). The time of sensor placement will be recorded.
Device: Celsi Warmer
A trained study clinician will attach the Celsi Warmer temperature sensor to the abdomen and secure it with the abdominal belt according to the device's instruction manual (such that the temperature sensor is positioned using a vertical line from the mid-clavicular line and just below the ribs). The time of sensor placement will be recorded.




Primary Outcome Measures :
  1. Broad Objective - Comparison to the Gold Standard of Rewarming Hypothermic Newborns [ Time Frame: 1 year ]
    To evaluate the clinical efficacy and safety of the Celsi Warmer in rewarming hypothermic newborns by comparing the Celsi Warmer's accuracy in measuring neonatal temperature compared to the gold standard, axillary temperature readings.


Secondary Outcome Measures :
  1. Efficacy of the Device [ Time Frame: 1 year ]
    To assess the performance of the Celsi Warmer in rewarming hypothermic newborns by measuring the incidence of attainment of normothermia (36.5-37.5°C)

  2. Safety of the Device - Rate of Temperature Increase [ Time Frame: 1 year ]
    To measure the infant's rate of temperature (°C) increase through thermoregulatory intervention.

  3. Safety of the Device - Local effect of the Abdominal Belt [ Time Frame: 1 year ]
    To evaluate the local effect of the abdominal belt on newborn's skin by looking at any evidence of skin irritation

  4. Safety of the Device - Incidence of Hyperthermia [ Time Frame: 1 year ]
    To evaluate any incidence of hyperthermia (>37.5°C) during the thermoregulation intervention.

  5. Safety of the Device - Incidence of Rebound Hypothermia [ Time Frame: 1 year ]
    To report any incidence of rebound hypothermia ( < 36.5°C) (post-intervention hypothermia) up to 72 hours from the initial encounter



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   1 Day to 28 Days   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Any neonate who:

  1. Is currently being treated at study location,
  2. Is an inborn admission to the neonatal ward,
  3. Whose parents or guardians provided informed consent,
  4. Whose parents or guardians providing informed consent are 18 years old or older,
  5. Has a current weight of greater than or equal to 1.0 kg and less than or equal to 4.0 kg,
  6. Has been identified as in need of thermal care defined as having a moderate to severe hypothermic temperature (32.0-36.0 °C) as the last temperature recorded in hospital chart, or during recruitment procedures; and
  7. is unable to be enrolled in Kangaroo Mother Care (KMC) for reasons including, but not limited to: a. Mother/guardian unable or unavailable to provide KMC b. Under observation in the Neonatal Intensive Care Unit (NICU) before transfer to KMC c. No space in KMC d. Clinician's discretion;
  8. May be receiving other medical treatments, including but not limited to, Continuous Positive Airway Pressure (CPAP), oxygen therapy, intravenous (IV) fluids, management and monitoring of common newborn conditions such as hypoglycemia, and/or hyperbilirubinemia.

Exclusion Criteria:

  1. Requires mechanical ventilation;
  2. Is deemed in need of intensive care by the hospital staff who is providing care, including but not limited to: a. neonates with severe anemia and/or any suspected hematological disorders, and/or b. Neonates with obvious congenital anomalies, and/or c. neonates suspected with hypo/hyperthyroidism or any hormonal disorders;
  3. has been diagnosed with birth asphyxia;
  4. Presents a condition that precludes the use of the temperature sensor and/or abdominal belt including but not limited to, known umbilical cord infection, known skin infection;
  5. Whose clinician presents concerns about their participation;
  6. Is receiving treatment that participation in the study would interfere with (e.g. transferring to KMC).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06003140


Contacts
Layout table for location contacts
Contact: Rebecca Massey, MPH, BSN, RN 7133482923 rebecca.elias@rice.edu
Contact: Sonia Sosa Saenz, BME soniasosa@rice.edu

Locations
Layout table for location information
Nigeria
University of Lagos, Lagos, Nigeria Recruiting
Lagos, Nigeria
Contact: Chinyere Ezeaka, MBBS         
Sponsors and Collaborators
William Marsh Rice University
University of Lagos, Nigeria
Investigators
Layout table for investigator information
Principal Investigator: Chinyere Ezeaka, MBBS, MPH College of Medicine, University of Lagos, Lagos, Nigeria
Publications:
Layout table for additonal information
Responsible Party: William Marsh Rice University
ClinicalTrials.gov Identifier: NCT06003140    
Other Study ID Numbers: 2023-69
First Posted: August 21, 2023    Key Record Dates
Last Update Posted: August 23, 2023
Last Verified: August 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypothermia
Body Temperature Changes